Home » Stocks » KROS

Keros Therapeutics, Inc. (KROS)

Stock Price: $37.68 USD 1.08 (2.95%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
Market Cap 877.83M
Revenue (ttm) 2.50M
Net Income (ttm) -48.55M
Shares Out 23.30M
EPS (ttm) -2.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $37.68
Previous Close $36.60
Change ($) 1.08
Change (%) 2.95%
Day's Open 36.80
Day's Range 36.54 - 38.32
Day's Volume 87,160
52-Week Range 28.02 - 88.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

LEXINGTON, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

1 month ago - GlobeNewsWire

LEXINGTON, Mass., May 12, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializati...

2 months ago - GlobeNewsWire

LEXINGTON, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development an...

2 months ago - GlobeNewsWire

LEXINGTON, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development ...

4 months ago - GlobeNewsWire

LEXINGTON, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development ...

4 months ago - GlobeNewsWire

LEXINGTON, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

5 months ago - GlobeNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other stocks mentioned: CAR, BH, GSKY, GTHX, ORGO, REYN, WTRH
8 months ago - Benzinga

LEXINGTON, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

8 months ago - GlobeNewsWire

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

8 months ago - GlobeNewsWire

LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

8 months ago - GlobeNewsWire

LEXINGTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development a...

8 months ago - GlobeNewsWire

LEXINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializat...

8 months ago - GlobeNewsWire

LEXINGTON, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development a...

9 months ago - GlobeNewsWire

Following an active September, two IPOs are scheduled to raise $200 million in the week ahead.

Other stocks mentioned: FUBO
9 months ago - Seeking Alpha

LEXINGTON, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerciali...

10 months ago - GlobeNewsWire

LEXINGTON, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, developmen...

10 months ago - GlobeNewsWire

LEXINGTON, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializ...

11 months ago - GlobeNewsWire

LEXINGTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development...

11 months ago - GlobeNewsWire

LEXINGTON, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development...

11 months ago - GlobeNewsWire

LEXINGTON, Mass, June 26, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development ...

1 year ago - GlobeNewsWire

Health care companies and governments are racing to find a vaccine or other effective treatment for Covid-19 -- so investors have been piling into stocks like Gilead Sciences, Moderna and Novavax.

Other stocks mentioned: BIO, FMTX, IMRA, PCVX, RNA, RPTX, XBI ...
1 year ago - CNN Business

Keros Therapeutics (KROS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

LEXINGTON, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializ...

1 year ago - GlobeNewsWire

LEXINGTON, Mass., May 22, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercializa...

1 year ago - GlobeNewsWire

Keros Therapeutics Inc (NASDAQ: KROS), a clinical-stage biopharma focused on the development of treatments for rare hematologic and musculoskeletal disorders, went public in April.

1 year ago - Benzinga

These companies just raised significant cash to advance promising drug pipelines.

Other stocks mentioned: ZNTL
1 year ago - The Motley Fool

The Covid-19 pandemic has waylaid what was supposed to be an active year in biotech initial public offerings.

1 year ago - GuruFocus

LEXINGTON, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commerciali...

1 year ago - GlobeNewsWire

Keros Therapeutics finished the week up 35%, affirming that the biotech industry won't be deterred by current market volatility.

1 year ago - Seeking Alpha

About KROS

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also develop... [Read more...]

Industry
Biotechnology
IPO Date
Apr 8, 2020
Stock Exchange
NASDAQ
Ticker Symbol
KROS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for KROS stock is "Buy." The 12-month stock price forecast is 87.50, which is an increase of 132.22% from the latest price.

Price Target
$87.50
(132.22% upside)
Analyst Consensus: Buy